NASDAQ · Biotechnology

Jade Biosciences, Inc. (JBIO) Stock

$14.39 +1.70% NASDAQ: JBIO Healthcare

Valuation

MetricValue
Price$14.39
Market Cap$875.77M
P/E Ratio-5.13
P/B Ratio1.96
P/S Ratio0.00
EPS (TTM)$-4.06
52-Week High$28.00
52-Week Low$8.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.11%
ROA-32.46%
ROCE-37.39%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio19.76

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-53.0M$-81.0M$-75.0M$-114.0M
Net Profit$-23.0M$-52.0M$-76.0M$-70.0M$-127.0M
EPS$-32.96$-73.67$-100.38$-85.26$-4.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$175.0M$135.0M$127.0M$80.0M$350.0M
Total Liabilities$3.0M$9.0M$18.0M$4.0M$17.0M
Cash$54.0M$22.0M$23.0M$34.0M$88.0M
Borrowings$1.0M$1.0M$1.0M$0$1.0M

Latest News

Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics MT Newswires · Jul 2, 2026 Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? Insider Monkey · Jun 30, 2026 Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors GlobeNewswire · Jun 26, 2026 Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Jun 5, 2026 Jade Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-27.0M$-39.0M$-57.0M$-71.0M$-95.0M
Investing Cash Flow$-114.0M$7.0M$12.0M$56.0M$-247.0M
Financing Cash Flow$0$0$0$0$171.0M
Net Cash Flow$50.0M$-32.0M$1.0M$10.0M$19.0M
Free Cash Flow$-28.0M$-39.0M$-57.0M$-71.0M$-95.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-4.82
FCF Yield-14.38%
Quick Ratio14.93
Interest Coverage0.00
Return 1Y125.26%
Return 3Y-96.61%
Return 5Y-95.78%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRSAclaris Therapeutics, Inc. $3.83 +1.06% -8.88 $534.91M 0.00%
CTNMContineum Therapeutics, Inc. $13.38 +1.52% -7.58 $503.37M 0.00%
DWTXDogwood Therapeutics, Inc. $1.40 -0.71% -0.18 $47.08M 0.00%
ELDNEledon Pharmaceuticals, Inc. $2.48 +2.48% -2.53 $191.43M 0.00%
KYTXKyverna Therapeutics, Inc. $6.39 +3.40% -2.33 $388.48M 0.00%

About Jade Biosciences, Inc.

Jade Biosciences, Inc. is led by CEO Tom Frohlich, publicly traded since 2025.

Jade Biosciences, Inc. (JBIO) stock trades at $14.39 with a market capitalization of $875.77M. The stock is valued at a price-to-earnings (P/E) ratio of -5.13, price-to-book of 1.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.20 and $28.00, and currently trades 48.6% below its 52-week high.

On profitability, Jade Biosciences, Inc. generates a return on equity (ROE) of -49.11%, return on capital employed of -37.39%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides